Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
Now Approved!
Who We Are
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
Our Technology
EyePoint has developed five products approved by the FDA for, sustained-release delivery of drugs to the eye.
Our Pipeline
EyePoint has a number of products in development that utilize our proven DurasertTM and Verisome Technology platforms®.
About EyePoint
Words of Wisdom, Inspiration, and Hope from Top Ophthalmologists
Latest EyePoint News
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
- EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
- EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments
- EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®